{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:06:55Z","timestamp":1772136415628,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"La Ligue Contre le Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Programme XU GUANGQI"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006331","name":"Canceropole PACA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006331","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-11931-w","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T09:19:48Z","timestamp":1753521588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mechanisms of induced resistance to the antitumoral agent ZZW-115 in pancreas ductal adenocarcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Patricia","family":"Santofimia-Casta\u00f1o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matias","family":"Estaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Cosialls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Fraunhoffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Chuluyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Iovanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"11931_CR1","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/ijc.31963","volume":"144","author":"G Augello","year":"2019","unstructured":"Augello, G. et al. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. Int. J. Cancer 144, 2613\u20132624 (2019).","journal-title":"Int. J. Cancer"},{"key":"11931_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.bbrc.2015.09.082","volume":"466","author":"Y Bak","year":"2015","unstructured":"Bak, Y., Shin, H. J., Bak, I., Yoon, D. Y. & Yu, D. Y. Hepatitis B virus X promotes hepatocellular carcinoma development via nuclear protein 1 pathway. Biochem. Biophys. Res. Commun. 466, 676\u2013681 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"11931_CR3","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1166\/jbn.2018.2557","volume":"14","author":"C Botto","year":"2018","unstructured":"Botto, C. et al. Cationic solid lipid nanoparticles as non viral vectors for the inhibition of hepatocellular carcinoma growth by RNA interference. J. Biomed. Nanotechnol. 14, 1009\u20131016 (2018).","journal-title":"J. Biomed. Nanotechnol."},{"key":"11931_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41575-019-0179-x","volume":"16","author":"J Bruix","year":"2019","unstructured":"Bruix, J., da Fonseca, L. G. & Reig, M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 16, 617\u2013630 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"11931_CR5","first-page":"421","volume":"35","author":"J Bruix","year":"2001","unstructured":"Bruix, J. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. Eur. Assoc. Study Liver J. Hepatol. 35, 421\u2013430 (2001).","journal-title":"Eur. Assoc. Study Liver J. Hepatol."},{"key":"11931_CR6","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.7150\/thno.29628","volume":"9","author":"CY Chen","year":"2019","unstructured":"Chen, C. Y. et al. Induction of nuclear protein-1 by thyroid hormone enhances platelet-derived growth factor A mediated angiogenesis in liver cancer. Theranostics 9, 2361\u20132379 (2019).","journal-title":"Theranostics"},{"key":"11931_CR7","doi-asserted-by":"publisher","first-page":"e27186","DOI":"10.1371\/journal.pone.0027186","volume":"6","author":"MH Chen","year":"2011","unstructured":"Chen, M. H. et al. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. PLoS ONE 6, e27186 (2011).","journal-title":"PLoS ONE"},{"key":"11931_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1158\/1541-7786.MCR-17-0109","volume":"15","author":"A de Conti","year":"2017","unstructured":"de Conti, A. et al. Inhibition of the cell death pathway in nonalcoholic steatohepatitis (NASH)-related hepatocarcinogenesis is associated with histone H4 lysine 16 deacetylation. Mol. Cancer Res. MCR 15, 1163\u20131172 (2017).","journal-title":"Mol. Cancer Res. MCR"},{"key":"11931_CR9","doi-asserted-by":"publisher","first-page":"e2269","DOI":"10.1038\/cddis.2016.175","volume":"7","author":"MR Emma","year":"2016","unstructured":"Emma, M. R. et al. NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance. Cell Death Dis. 7, e2269 (2016).","journal-title":"Cell Death Dis."},{"key":"11931_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245\u20131255 (2012).","journal-title":"Lancet"},{"key":"11931_CR11","first-page":"782","volume":"31","author":"H Huang","year":"2015","unstructured":"Huang, H. et al. Nuclear protein 1 knockdown inhibits proliferation and migration of HepG2 cells. Xi bao yu fen zi mian yi xue za zhi = Chin. J. Cell. Mol. Immunol. 31, 782\u2013786 (2015).","journal-title":"Xi bao yu fen zi mian yi xue za zhi = Chin. J. Cell. Mol. Immunol."},{"key":"11931_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000489744","volume":"47","author":"Y Ji","year":"2018","unstructured":"Ji, Y. et al. Serum from chronic hepatitis B patients promotes growth and proliferation via the IGF-II\/IGF-IR\/MEK\/ERK signaling pathway in hepatocellular carcinoma cells. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 47, 39\u201353 (2018).","journal-title":"Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol."},{"key":"11931_CR13","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/hep.27976","volume":"62","author":"YK Lee","year":"2015","unstructured":"Lee, Y. K. et al. Identification of a mitochondrial defect gene signature reveals NUPR1 as a key regulator of liver cancer progression. Hepatology 62, 1174\u20131189 (2015).","journal-title":"Hepatology"},{"key":"11931_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.5483\/BMBRep.2015.48.11.180","volume":"48","author":"YK Lee","year":"2015","unstructured":"Lee, Y. K., Woo, H. G. & Yoon, G. Mitochondrial defect-responsive gene signature in liver-cancer progression. BMB Rep. 48, 597\u2013598 (2015).","journal-title":"BMB Rep."},{"key":"11931_CR15","doi-asserted-by":"publisher","first-page":"39732","DOI":"10.1038\/srep39732","volume":"7","author":"JL Neira","year":"2017","unstructured":"Neira, J. L. et al. Identification of a drug targeting an intrinsically disordered protein involved in pancreatic adenocarcinoma. Sci. Rep. 7, 39732 (2017).","journal-title":"Sci. Rep."},{"key":"11931_CR16","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1038\/sj.onc.1207559","volume":"23","author":"P Nicotera","year":"2004","unstructured":"Nicotera, P. & Melino, G. Regulation of the apoptosis-necrosis switch. Oncogene 23, 2757\u20132765 (2004).","journal-title":"Oncogene"},{"key":"11931_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10585-015-9720-7","volume":"32","author":"N Pedrola","year":"2015","unstructured":"Pedrola, N. et al. Nidogen 1 and nuclear protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion. Clin. Exp. Metas. 32, 467\u2013478 (2015).","journal-title":"Clin. Exp. Metas."},{"key":"11931_CR18","doi-asserted-by":"publisher","first-page":"e1612678","DOI":"10.1080\/23723556.2019.1612678","volume":"6","author":"P Santofimia-Castano","year":"2019","unstructured":"Santofimia-Castano, P. et al. Designing and repurposing drugs to target intrinsically disordered proteins for cancer treatment: using NUPR1 as a paradigm. Mol. Cell. Oncol. 6, e1612678 (2019).","journal-title":"Mol. Cell. Oncol."},{"key":"11931_CR19","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1172\/JCI127223","volume":"129","author":"P Santofimia-Castano","year":"2019","unstructured":"Santofimia-Castano, P. et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J. Clin. Investig. 129, 2500\u20132513 (2019).","journal-title":"J. Clin. Investig."},{"key":"11931_CR20","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm, S. M. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129\u20133140 (2008).","journal-title":"Mol. Cancer Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11931-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11931-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11931-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T01:17:02Z","timestamp":1757294222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11931-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11931"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-11931-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6399686\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27242"}}